1. Volume 374, Issue 9694, Pages 989-997 (September 2009)
Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials 
Dr Michelle L O'Donoghue, MD, Prof Eugene Braunwald, MD, Prof Elliott M Antman, MD, Sabina A Murphy, MPH, Prof Eric R Bates, MD, Prof Yoseph Rozenman, MD, Alan D Michelson, MD, Raymond W Hautvast, MD, Peter N Ver Lee, MD, Sandra L Close, PhD, Lei Shen, PhD, Jessica L Mega, MD, Marc S Sabatine, MD, Stephen D Wiviott, MD 
The Lancet 
Volume 374, Issue 9694, Pages (September 2009)
DOI: /S (09)
Copyright © 2009 Elsevier Ltd Terms and Conditions

2. Figure 1 Mean inhibition of platelet aggregation
Inhibition of platelet aggregation (IPA) to 20 μM ADP at prespecified timepoints after a 600 mg loading dose of clopidogrel or 60 mg loading dose of prasugrel stratified by the use of a PPI in the PRINCIPLE-TIMI 44 trial. PPI=proton-pump inhibitor. *p<0·05 for comparison between users and non-users of a PPI.
The Lancet  , DOI: ( /S (09) )
Copyright © 2009 Elsevier Ltd Terms and Conditions

3. Figure 2
Proportion of non-responders (defined as IPA<20% to 20 μM ADP) 6 h (A) and 15 days (B) after clopidogrel or prasugrel and stratified by the use of a PPI in PRINCIPLE-TIMI 44
PPI=proton-pump inhibitor. IPA=inhibition of platelet aggregation.
The Lancet  , DOI: ( /S (09) )
Copyright © 2009 Elsevier Ltd Terms and Conditions

4. Figure 3
Unadjusted cumulative incidence of CV death, MI, or stroke through long-term follow-up
Patients were or were not on a PPI in combination with clopidogrel or prasugrel in the TRITON-TIMI 38 trial. CV=cardiovascular. MI=myocardial infarction. PPI=proton-pump inhibitor.
The Lancet  , DOI: ( /S (09) )
Copyright © 2009 Elsevier Ltd Terms and Conditions